论文部分内容阅读
目的比较GP方案(吉西他滨+顺铂)和NP方案(长春瑞滨+顺铂)治疗晚期非小细胞肺癌的近期疗效和毒副反应。方法50例非小细胞肺癌中,26例应用GP方案,24例应用NP方案。2个周期后评定疗效和毒副反应。结果GP组有效率38.5%,1年生存率34.6%;NP组有效率为37.5%,1年生存率37.5%。两组有效率、1年生存率比较差异无显著性(P=0.956,P=0.865)。骨髓抑制为主要毒副反应,其中GP组Ⅲ-Ⅳ度血小板减少发生率高于NP组(P=0.027),非血液学毒副反应中静脉炎发生率NP组高于GP组(P=0.037)。结论GP方案与NP方案治疗晚期非小细胞肺癌,疗效肯定,毒副反应可耐受。
Objective To compare the short-term effects and side effects of GP regimen (gemcitabine plus cisplatin) and NP regimen (vinorelbine plus cisplatin) in the treatment of advanced non-small cell lung cancer. Methods Fifty patients with non-small cell lung cancer were treated with GP regimen in 26 cases and NP regimen in 24 cases. After 2 cycles to assess the efficacy and toxicity. Results The effective rate of GP group was 38.5% and the 1-year survival rate was 34.6%. The effective rate of NP group was 37.5% and the 1-year survival rate was 37.5%. Two groups of effective, 1-year survival rate was no significant difference (P = 0.956, P = 0.865). Myelosuppression was the main side effect. The incidence of grade Ⅲ-Ⅳ thrombocytopenia in GP group was higher than that in NP group (P = 0.027). The incidence of phlebitis in non-hematological toxicity was higher in NP group than in GP group (P = 0.037 ). Conclusion The GP regimen and NP regimen are effective in treating advanced non-small cell lung cancer with tolerable toxic and side effects.